Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of itepekimab safety and tolerability in COPD
CTR20241409Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of itepekimab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started May 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20241409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241409.